Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement

Project Information

NEOpTTL

Grant agreement ID: 190185439

DOI

10.3030/190185439

Project closed

EC signature date 21 November 2023

Start date 1 November 2023

End date 31 January 2026

Funded under

• The European Innovation Council (EIC)

Total cost

€ 8 422 865,06

EU contribution

€ 2 500 000,00

Coordinated by

NEOGAP THERAPEUTICS AB
Sweden

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Conference proceedings (1)

Personalized tumor-trained lymphocytes – a neoantigen targeted T cell therapy product for treatment of colorectal cancer

Author(s): Gafvelin et al.
Published in: Journal for ImmunoTherapy of Cancer (JITC)
Publisher: BMJ - Society for Immunotherapy of Cancer.